The Transformative Drug Impact of AI in Pharmaceutical Drug Product Development

The pharmaceutical industry plays a vital role in addressing global healthcare challenges and responding to medical emergencies. This responsibility relies heavily on continuous innovation and the integration of cutting-edge technologies. Core components of pharmaceutical innovation include rigorous research and development (R&D), optimization of manufacturing processes, strategic packaging, and patient-focused marketing approaches [2]. However, traditional drug development is often a lengthy, expensive process with high failure rates, particularly when developing novel therapies or managing complex manufacturing systems. Each stage of the pharmaceutical product lifecycle—ranging from drug discovery and formulation to quality testing, marketing, and post-market surveillance—can benefit from Artificial Intelligence (AI). By integrating AI, these processes can be made more efficient, safe, and effective [3]. AI offers powerful tools for accelerating drug development, from early target identification to clinical trials. In fact, the AI drug discovery market, valued at around $1.94 billion in 2025, is projected to surge to approximately $16.49 billion by 2034, reflecting its transformative impact on pharmaceutical R&D. Beyond development, AI also has the potential to revolutionize pharmaceutical regulatory affairs. It can streamline activities such as dossier preparation, document review and archiving, data extraction, compliance auditing, and quality management. The integration of AI in regulatory processes marks the beginning of a new era in human-AI collaboration within the pharmaceutical sector [4]. Regulatory bodies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) are actively exploring AI adoption and are currently engaging with stakeholders to gather feedback and shape future implementation strategies.

MATERIALS AND METHODS

This review is based on a comprehensive analysis of literature and data sources spanning from 2017 to 2025. The research involved examining peer-reviewed journal articles, industry reports, regulatory publications, and market research studies. Key search terms used included “AI in drug discovery,” “machine learning in pharmaceuticals,” “generative AI for molecule design,” and “AI in regulatory affairs.” Relevant data were primarily collected from databases such as PubMed, Scopus, and Google Scholar, which served as the foundation for this review.

3) AI Tool Application in Dosage Form Design

In drug delivery research, the human body is often modeled as a series of compartments, with biological membranes playing a crucial role in determining how medications are absorbed and distributed. The rate at which a drug permeates these membranes—largely influenced by the chosen route of administration—is a key factor in evaluating the effectiveness of a dosage form. While passive diffusion depends on the chemical properties of the drug, active transport involves more complex biological mechanisms, such as membrane-bound transport systems. [5] To better understand pharmacokinetic behavior, modern computational models have been introduced. Predictive accuracy in preclinical models, based on defined parameters, is a major focus in pharmaceutical R&D. AI technologies significantly enhance this area by enabling the analysis of complex, multi-layered datasets, leading to deeper insights into drug behavior. [6] Artificial Intelligence—particularly tools like artificial neural networks—can be employed to conduct advanced pharmacokinetic studies. These tools also integrate and analyze large-scale databases, including chemical, genomic, and phenotypic data, to better understand drug interactions and molecular functions. Additionally, AI-driven approaches help evaluate how different drug delivery methods influence pharmacokinetics, ultimately contributing to a more comprehensive understanding of drug disposition and potential toxicity. [7, 8] AI significantly contributes to both drug development and drug repurposing efforts—particularly in identifying new therapeutic uses for existing medications. Patient-specific factors, such as medical conditions and treatment needs, are essential considerations in formulation design, pharmacokinetics, and overall drug development. One of the main challenges in fully implementing AI for drug delivery system design is the limited availability of comprehensive and high-quality data. However, AI excels at utilizing existing datasets, processing large volumes of complex information, and enhancing knowledge bases through advanced self-supervised learning techniques and accurate parameter tracking. By enabling predictive modeling of drug distribution, analyzing drug interactions, and optimizing delivery mechanisms, AI plays a pivotal role in advancing drug delivery science. Ultimately, the integration of AI tools and databases enhances both the efficiency and effectiveness of drug delivery systems across diverse clinical applications. [9,10]

4) AI in Drug Delivery

The integration of AI and big data analytics in the pharmaceutical industry has given rise to the field of computational pharmaceutics, which focuses on optimizing drug delivery systems through advanced multiscale modeling techniques. By leveraging AI algorithms and machine learning, researchers can analyze vast datasets to predict drug behavior more accurately. This enables the simulation of multiple delivery scenarios, significantly reducing the reliance on traditional trial-and-error experimentation. [11] As a result, the drug development process becomes faster, more cost-effective, and more efficient. Computational pharmaceutics also provides valuable insights into drug–body interactions, paving the way for more personalized and targeted therapies. Furthermore, incorporating AI into drug delivery design helps identify possible side effects or drug–drug interactions early in the process, thereby enhancing patient safety and minimizing adverse outcomes. [12,13]

5) AI in Drug Delivery System Design and Oral Solid Dosage Forms

AI algorithms are increasingly used to analyze the complex relationships between drug properties, formulation ingredients, and physiological conditions. This enables accurate prediction of drug behavior across multiple levels, offering a deeper understanding of drug delivery mechanisms and supporting the development of more efficient delivery systems. AI can forecast key characteristics such as a drug’s physicochemical properties, its in vitro release profile, and overall stability. [14] These same tools also help refine in vivo pharmacokinetic parameters, improve drug distribution, and strengthen in vitro–in vivo correlation (IVIVC) studies. By applying the right combination of AI technologies, researchers can identify potential challenges in drug delivery systems early in the development process. This allows for timely adjustments and proactive risk mitigation, ultimately optimizing the final product. [15] When it comes to oral solid dosage forms—one of the most widely used formats in the pharmaceutical I ndustry—AI plays a crucial role. It assists in identifying optimal formulations and refining key process parameters. Technologies such as artificial neural networks (ANNs), fuzzy logic systems, and evolutionary algorithms are employed to understand and control processing variables, ensuring consistent and reliable outcomes. [16, 17] Tablets, which make up a significant share of drug delivery products, are composed of active pharmaceutical ingredients (APIs) and excipients. These components are compressed or molded into the desired shape and size. Excipients are added to influence essential factors like disintegration time, dissolution rate, and drug release profiles. AI can support systemic drug delivery by predicting release behavior and evaluating how critical manufacturing variables impact tablet performance, ensuring high standards of quality control. [18] Moreover, certain AI applications are now being used to detect physical defects in tablets, further enhancing product quality and consistency. [19] The ability to accurately predict drug release based on formulation parameters plays a vital role in ensuring consistent quality control. Drug release is typically evaluated through both in vivo and in vitro methods, which are fundamental technologies regularly utilized throughout the product development process. In the context of pharmaceutical formulation, AI is increasingly being used to forecast drug release profiles. This predictive capability reduces the number of experimental trials needed to optimize formulations, thereby minimizing time, labor, and costs during pilot-scale and production phases. ²¹ [20] AI also contributes to predicting dissolution rates and disintegration times, which are critical for selecting the most suitable batch for further scaling and manufacturing. [ 21] This data-driven approach improves efficiency and enhances decision-making throughout the development lifecycle.

6) AI in Nanomedicine

The application of artificial intelligence (AI) in nanomedicine holds significant promise, especially in areas such as data analysis, pattern recognition, and optimization. By leveraging these capabilities, AI can accelerate the development of innovative nanoscale therapies, enhance diagnostic accuracy, optimize drug delivery systems, and contribute to the advancement of personalized medicine. [ 22,23] One of AI's most transformative roles in nanomedicine is enabling highly targeted and precise treatment strategies at the nanoscale, potentially revolutionizing how healthcare is delivered. Nanoparticles play a crucial role in modern drug delivery systems, and AI algorithms assist researchers in designing and optimizing these particles by predicting essential factors such as physicochemical properties, stability, and therapeutic effectiveness. [24] To effectively utilize nanomedicines—especially in complex areas like cancer therapy—AI supports key processes such as drug selection, dosage optimization, and the identification of stimuli-responsive materials. In particular, deep learning models have demonstrated high accuracy in melanoma diagnosis and treatment, significantly improving patient outcomes and clinical decision-making. [25] AI algorithms also play a crucial role in simulating the behavior and interactions of nanoscale materials within biological environments. [26] This modeling capability enables researchers to predict how nanoparticles behave, understand drug release kinetics, and assess potential toxicity, all of which are essential for designing safe and effective nanomedicine formulations. [27] In addition, AI is increasingly being integrated into nanosensors and biosensors used for real-time monitoring of biomarkers, drug concentrations, and disease progression. These smart sensing systems provide continuous feedback to healthcare professionals, supporting timely interventions and allowing for personalized adjustments to treatment plans. [28]

Applicability of AI in Parenteral, Transdermal, and Mucosal Routes

Artificial intelligence (AI) plays a vital role in the development and manufacturing of complex pharmaceutical formulations, including injectables and biologics. By analyzing formulation components and manufacturing processes, AI systems help predict key physicochemical properties such as pH, solubility, stability, and viscosity. This enables the design of stable parenteral formulations with improved quality, efficiency, and consistency. [29,30] AI algorithms are also instrumental in optimizing parenteral product manufacturing by identifying critical process parameters that affect product quality. Real-time process data analysis helps enhance product uniformity, reduce batch failures, and increase overall production efficiency. By evaluating large datasets from analytical methods like particle size analysis and chromatography, AI detects patterns and deviations that allow for early identification and resolution of quality issues, ensuring a smoother production workflow. In visual inspection, AI assists in monitoring particle behavior inside containers, distinguishing particles that are swimming, sinking, or adhering to surfaces. Techniques such as particle tracking combined with deep learning algorithms provide precise detection and isolation of particles. [31] Additionally, AI-powered image processing addresses manufacturing defects such as bubble formation in parenteral batches. Beyond product quality, AI supports maintenance operations for sophisticated manufacturing equipment by analyzing sensor data, equipment performance history, and maintenance logs. This predictive maintenance approach forecasts equipment failures, enabling timely interventions that minimize downtime, enhance productivity, and reduce maintenance costs. [32]

7) AI in Pharmacokinetics and Pharmacodynamics

The drug development process is complex, involving multiple stages such as drug discovery, preclinical testing, clinical trials, and regulatory approval. Key to this process are pharmacokinetics (PK) and pharmacodynamics (PD), which help determine the optimal dosage, delivery method, and safety profile of a medication within the body. Traditional experimental methods for studying PK and PD, including animal testing and human clinical trials, can be time-consuming, expensive, and sometimes yield unreliable predictions of therapeutic outcomes and safety. These methods also face ethical concerns, limitations in sample size, and variability between individuals. [33] To address these challenges, computational models and artificial intelligence (AI) technologies have emerged as effective tools for predicting pharmacokinetic and pharmacodynamic behavior. AI offers a faster, more economical, and often more accurate alternative, improving the efficiency of drug development and increasing confidence in safety and efficacy predictions. [34] AI has demonstrated considerable potential in the fields of pharmacokinetics (PK), pharmacodynamics (PD), and drug discovery. With advances in powerful computational techniques and machine learning algorithms, AI has become an effective tool for predicting and optimizing drug PK and PD profiles. Although challenges remain—such as the need for large datasets and concerns about data reliability—AI continues to offer promising opportunities to advance PKPD research and improve therapeutic outcomes. [35]

8) The Role of AI in Disease Diagnosis

Effective treatment planning and ensuring patient well-being fundamentally depend on accurate disease diagnosis. However, human errors and the potential for misinterpretation present significant challenges to achieving diagnostic precision. In this context, Artificial Intelligence (AI) has emerged as a powerful tool, offering enhanced accuracy and efficiency in medical analysis. A thorough review of current literature highlights a wide range of AI technologies and methodologies being applied to disease diagnosis. The growing global population, coupled with diverse environmental influences, has increased the pressure on healthcare systems to deliver timely and accurate diagnoses. [36] Despite certain limitations and inconsistencies in existing diagnostic methods, recent advancements demonstrate promising new approaches that address previously uncharted diagnostic scenarios. One such approach involves stratifying patients based on the severity of their condition—an area where AI plays a critical role. Diagnosis, typically based on the identification of existing health problems, greatly benefits from the maintenance of detailed medical records. These records support the analysis of examination and test results, enabling more personalized and timely healthcare responses. [37] Traditional clinician-led diagnostics can be subjective, varying from one practitioner to another. This highlights the need for more objective, data-driven diagnostic methods. AI addresses this need by enabling early disease detection—particularly in conditions like cancer and dementia—through predictive analysis. Current AI-driven diagnostic systems leverage technologies such as deep learning, neural networks, and sophisticated algorithms to collect, process, and interpret complex medical data. These systems rely on unbiased algorithms trained with high-quality datasets, leading to more accurate and reliable disease predictions. [38]

9) AI Techniques in Medical Diagnostics

Deep learning models have the ability to adapt to evolving data patterns, thereby improving the accuracy of predictions over time. In particular, unsupervised learning has shown promise in diagnosing conditions such as hepatitis. While the use of larger and more diverse datasets enhances the potential of AI in healthcare, it can also result in outcomes that are complex and challenging to interpret. Deep learning applications in diagnostics have expanded significantly, with notable successes in classifying dermatological conditions and detecting atrial fibrillation. One commonly used evaluation method in this context is cross-validation, which involves randomly dividing data into multiple subsets to test and refine algorithm performance. The effectiveness of AI in diagnostics is typically assessed using three core metrics: accuracy, sensitivity, and specificity—all essential in evaluating model reliability and clinical relevance. A comprehensive literature review indicates that various machine learning approaches—such as support vector machines (SVM), k-nearest neighbors (KNN), random forests, decision trees, logistic regression, naive Bayes, discriminant analysis, and convolutional neural networks (CNNs)—can enhance diagnostic performance when applied to deep learning frameworks and neural networks. To analyze algorithmic performance effectively, factors like data origin, sample size, and the number of features in both training and test datasets must be considered. A noteworthy example includes the successful application of decision trees in combination with reasoning techniques for detecting liver diseases, illustrating the value of hybrid models in medical diagnostics. [39]

10) AI in Digital Therapy

Artificial Intelligence (AI) plays a vital role in transforming raw data into meaningful insights, making it a powerful tool in disease diagnosis, treatment planning, and therapeutic intervention. The use of advanced computational techniques in this rapidly evolving field offers promising applications across diverse areas of medical science. Tackling complex clinical challenges requires deep knowledge acquisition, thorough data analysis, and effective application—all of which are enhanced by the integration of AI. The development of medical AI solutions supports healthcare professionals in navigating and resolving difficult clinical scenarios with greater efficiency. Technologies such as artificial neural networks, evolutionary computing models, fuzzy expert systems, and hybrid intelligent systems are proving to be valuable assets. These tools assist medical practitioners in efficiently storing, managing, and processing vast amounts of healthcare data, ultimately contributing to more informed and timely clinical decisions. [40,41]

11) Limitations of AI in Healthcare and Drug Development

While AI-based models bring significant advantages to medical research and clinical applications, they also come with a set of limitations that must be carefully addressed. These challenges highlight the need to complement AI technologies with traditional experimental methods to ensure drug safety, reliability, and effectiveness. Key limitations include:

1]. Limited Data Availability

AI systems depend on large, high-quality datasets to produce reliable and accurate predictions. However, data scarcity—especially concerning rare diseases or underrepresented populations—can hinder model performance. When training datasets lack diversity or fail to reflect real-world demographics, the results may be biased or less applicable to broader patient groups. Therefore, it is essential to ensure that datasets are comprehensive, representative, and of high-quality during model development.

2]. Data Bias and Representation Issues

The accuracy of AI models is directly tied to the quality and neutrality of the training data. If the data contains inherent biases or is incomplete, the resulting predictions may be skewed. In clinical research, this often occurs when patient samples lack diversity, limiting the generalizability of the model. Such biases can lead to errors in assessing drug efficacy and safety. Developing AI tools that rely on unbiased, inclusive, and representative datasets is vital for trustworthy outcomes. [42]

3]. Difficulty in Integrating New Data

One significant limitation of many AI models is the challenge of updating them with new or emerging data. This is particularly problematic in fields like drug development, where new information is constantly being generated. Retraining or updating AI systems can be time-consuming and resource-intensive. Without timely updates, models risk becoming outdated, leading to inaccurate analyses and suboptimal decisions. Therefore, establishing efficient strategies for model maintenance and integration of fresh data is essential.

Additional Limitations of AI in Healthcare and Drug Development

In addition to data-related challenges, AI systems face several other critical limitations that affect their practical application in clinical and research settings. These include transparency issues, limited adaptability to patient variability, and difficulties in interpreting complex results.

4]. Lack of Transparency

Many AI models are often described as "black boxes" due to the complexity of their algorithms and the lack of clear insight into how decisions are made. This opacity makes it difficult to explain or justify the reasoning behind a model's predictions, which is a significant hurdle when seeking regulatory approval. Moreover, the inability to clearly trace how conclusions are reached can reduce trust among clinicians and researchers, particularly when AI-generated results contradict clinical intuition or experience. [43]

5]. Limited Ability to Handle Patient Variability

AI models, although trained on large and diverse datasets, may struggle to predict drug responses accurately for individuals whose characteristics fall outside the typical patterns seen in the data. This limitation is especially significant for medications that elicit a wide range of responses across different patient groups. High variability in response makes it challenging for AI to provide consistent and reliable predictions for all individuals. [44]

6]. Challenges in Interpreting Results

The complex nature of many AI systems can produce outputs that are difficult to interpret, even for domain experts. Without clear explanations for how predictions are made, clinicians and researchers may find it difficult to translate AI-generated results into meaningful clinical actions. Improving the interpretability and explainability of AI models is therefore essential to ensure their effective and confident use in real-world healthcare settings. [45]

7]. Ethical Considerations

The use of AI in healthcare raises important ethical questions, particularly around patient privacy, data ownership, and informed consent. Handling sensitive health data requires strict safeguards to ensure that individual rights are respected and confidentiality is maintained. Regulatory bodies play a vital role in establishing frameworks and guidelines to navigate these ethical complexities, ensuring responsible and transparent use of AI technologies. [46]

8]. Lack of Clinical Context and Expertise

While AI excels at identifying patterns and correlations within large datasets, it often lacks the ability to fully grasp the nuanced clinical implications of those patterns. This limitation becomes especially evident in personalized therapies, where treatment decisions are influenced by a wide range of individual factors—many of which may not be adequately captured in the data. The statistical approach of AI models may overlook these subtleties, highlighting the continued need for clinical expertise in interpreting results and guiding treatment strategies. [47]

RESULTS AND DISCUSSION

 AI in the Life Cycle Management of Pharmaceuticals

1. Drug Design & Screening

• Drug Design
  • Predicts target protein structures